Opportunities and challenges for the nasal administration of nanoemulsions

Current Topics in Medicinal Chemistry

Volumn 15, Issue 4, 2015, Pages 356-368

  Comfort, Claurice ^a   Garrastazu, Gabriela ^a,b   Pozzoli, Michele ^a   Sonvico, Fabio ^a  

^a UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^b Coordenação de Aperfeiçoamento de Pessoal de Nível Superior ^*  (Brazil)

Author keywords

Drug delivery; Mucosal vaccine; Nanoemulsions; Nasal delivery; Nose to brain; Pharmaceutical nanotechnology

Indexed keywords

ALKALINE PHOSPHATASE; ANTIHISTAMINIC AGENT; ANTIVIRUS AGENT; ARTEMETHER; BUSERELIN; BUTORPHANOL; CARBAMAZEPINE; CARVEDILOL; CELECOXIB; CLONAZEPAM; CORTICOSTEROID; CURCUMIN; DECONGESTIVE AGENT; DESMOPRESSIN; ERGOTAMINE; FENTANYL; HEPATITIS B SURFACE ANTIGEN; NALOXONE; NIFEDIPINE; NITRENDIPINE; OLANZAPINE; PROPRANOLOL; RIZATRIPTAN; ROPINIROLE; SUMATRIPTAN; TOLL LIKE RECEPTOR; TRIETHANOLAMINE; UNINDEXED DRUG; ZIPRASIDONE; ZOLMITRIPTAN; EMULSION; NANOMATERIAL;

ARTICLE; CELLULAR IMMUNITY; DIABETES INSIPIDUS; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; HUMAN; INTRANASAL DRUG ADMINISTRATION; MAXIMUM PLASMA CONCENTRATION; MEMBRANE PERMEABILITY; MIGRAINE; NANOEMULSION; NAUSEA AND VOMITING; NONHUMAN; NOSE DISEASE; OSTEOPOROSIS; PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; TIME TO MAXIMUM PLASMA CONCENTRATION; VACCINATION; ADMINISTRATION AND DOSAGE; CHEMISTRY; DRUG EFFECTS; EMULSION; METABOLISM; NOSE MUCOSA;

ADMINISTRATION, INTRANASAL; EMULSIONS; HUMANS; NANOSTRUCTURES; NASAL MUCOSA;

EID: 84946134030     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026615666150108144655     Document Type: Article

References (103)

1. Behl, C. R.; Pimplaskar, H. K.; Sileno, A. P.; deMeireles, J.; Romeo, V. D. Effects of physicochemical properties and other factors on systemic nasal drug delivery. Adv. Drug Deliv. Rev., 1998, 29(1-2), 89-116.
2. Li, C.; Xu, F.; Xie, D.; Jing, Y.; Shang, M.; Liu, G.; Wang, X.; Cai, S. Identification of absorbed constituents in the rabbit plasma and cerebrospinal fluid after intranasal administration of Asari Radix et Rhizoma by HS-SPME-GC-MS and HPLC-APCI-IT-TOF-MSn. Molecules, 2014, 19(4), 4857-4879.
3. Sarkar, M. A. Drug metabolism in the nasal mucosa. Pharm. Res., 1992, 9(1), 1-9.
4. Pardeshi, C. V.; Belgamwar, V. S. Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting. Expert Opin. Drug Deliv., 2013, 10(7), 957-972.
5. Ugwoke, M. I.; Agu, R. U.; Verbeke, N.; Kinget, R. Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv. Drug Deliv. Rev., 2005, 57(11), 1640-1665.
6. Mistry, A.; Stolnik, S.; Illum, L. Nanoparticles for direct nose-tobrain delivery of drugs. Int. J. Pharm., 2009, 379(1), 146-157.
7. Arora, P.; Sharma, S.; Garg, S. Permeability issues in nasal drug delivery. Drug Discov. Today, 2002, 7(18), 967-975.
8. Pires, A.; Fortuna, A.; Alves, G.; Falcão, A. Intranasal drug delivery: how, why and what for? J. Pharm. Pharm. Sci., 2009, 12(3), 288-311.
9. Alam, M. I.; Beg, S.; Samad, A.; Baboota, S.; Kohli, K.; Ali, J.; Ahuja, A.; Akbar, M. Strategy for effective brain drug delivery. Eur. J. Pharm. Sci., 2010, 40(5), 385-403.
10. Grassin-Delyle, S.; Buenestado, A.; Naline, E.; Faisy, C.; Blouquit-Laye, S.; Couderc, L.; Le Guen, M.; Fischler, M.; Devillier, P. Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids. Pharmacol. Ther., 2012, 134(3), 366-379.
11. Alagusundaram, M.; Chengaiah, C.; Gnanaprakash, K.; Ramkanth, S.; Chetty, C. M.; Dhachinamoorthi, D. Nasal drug delivery system- an overview. Int. J. Res. Pharm. Sci., 2010, 1(4), 454-465.
12. Rezaee, M.; Basri, M.; Raja Abdul Rahman, Raja Noor Zaliha; Salleh, A. B.; Chaibakhsh, N.; Fard Masoumi, H. R. A multivariate modeling for analysis of factors controlling the particle size and viscosity in palm kernel oil esters-based nanoemulsions. Ind. Crop. Prod., 2014, 52, 506-511.
13. Heunemann, P. Fundamental Research and Functionalisation of Nanoemulsions in Respect to Low-Energy Formation Processes, PhD Thesis, The Technical University of Berlin, Berlin, 2011.
14. Anton, N.; Benoit, J.; Saulnier, P. Design and production of nanoparticles formulated from nano-emulsion templates-A review. J. Controlled Release, 2008, 128(3), 185-199.
15. Bazylińska, U.; Kulbacka, J.; Wilk, K. A. Dicephalic ionic surfactants in fabrication of biocompatible nanoemulsions: Factors influencing droplet size and stability. Colloids Surf. Physicochem. Eng. Aspects, 2014.
16. Solans, C.; Izquierdo, P.; Nolla, J.; Azemar, N.; Garcia-Celma, M. J. Nano-emulsions. Curr. Opin. Colloid Interface Sci., 2005, 10(3-4), 102-110.
17. McClements, D. J. Nanoemulsions versus microemulsions: terminology, differences, and similarities. Soft Matter, 2012, 8(6), 1719-1729.
18. Anton, N.; Vandamme, T. F. Nano-emulsions and microemulsions: clarifications of the critical differences. Pharm. Res., 2011, 28(5), 978-985.
19. Tadros, T.; Izquierdo, P.; Esquena, J.; Solans, C. Formation and stability of nano-emulsions. Adv. Colloid Interface Sci., 2004, 108-109, 303-318.
20. Fischer, D. Polymeric Drug Delivery Systems For Encapsulating Hydrophobic Drugs. In Drug Delivery Strategies for Poorly Water-Soluble Drugs; Douroumis, D., Fahr, A., Eds.; John Wiley & Sons: Chicester, UK, 2012; pp. 199-224.
21. Izquierdo, P.; Esquena, J.; Tadros, T. F.; Dederen, C.; Garcia, M.; Azemar, N.; Solans, C. Formation and stability of nano-emulsions prepared using the phase inversion temperature method. Langmuir, 2002, 18(1), 26-30.
22. Khatri, S.; Lohani, P.; Gandhi, S. Nanoemulsions in Cancer Therapy. Indo. Global. J. Pharm. Sci., 2013, 3(2), 124-133.
23. Gibaud, S.; Attivi, D. Microemulsions for oral administration and their therapeutic applications. Expert Opin. Drug Deliv., 2012, 9(8), 937-951.
24. Capek, I. Degradation of kinetically-stable o/w emulsions. Adv. Colloid Interface Sci., 2004, 107(2-3), 125-155.
25. Pan, H.; Yu, L.; Xu, J.; Sun, D. Preparation of highly stable concentrated W/O nanoemulsions by PIC method at elevated temperature. Colloids Surf. A Physicochem. Eng. Asp., 2014, 447, 97-102.
26. Lovelyn, C.; Attama, A. A. Current state of nanoemulsions in drug delivery. J. Biomater. Nanobiotechnol., 2011, 2, 626-639.
27. Solans, C.; Solé, I. Nano-emulsions: formation by low-energy methods. Curr. Opin. Colloid Interface Sci., 2012, 17(5), 246-254.
28. Morais, J. M.; Burgess, D. J. Vitamin E nanoemulsions characterization and analysis. Int. J. Pharm., 2014, 465(1-2), 455-463.
29. Shafiq-un-Nabi, S.; Shakeel, F.; Talegaonkar, S.; Ali, J.; Baboota, S.; Ahuja, A.; Khar, R. K.; Ali, M. Formulation development and optimization using nanoemulsion technique: a technical note. AAPS pharmscitech, 2007, 8(2), E12-E17.
30. Brooks, B.W.; Richmond, H. Dynamics of liquid-liquid inversion using non-ionic surfactants. Colloids Surf., 1991, 58(1-2), 131-148.
31. Xie, F.; Brooks, B.W. Phase behaviour of a non-ionic surfactantpolymeric solution-water system during the phase inversion process. Colloids Suf. A, 2004, 252, 27-32.
32. Becher, S.E.; Schick, M.J. Macroemulsions. In: Surfactant Science Series, Nonionic Surfactants - Physical Chemistry. Schick, M.J., Ed.; Marcel Dekker: New York: Marcel Dekker Inc. (Ed.), 1987. Vol. 23, pp. 435-491.
33. Sajjadi, S.; Jahanzad, F.;, Brooks, B.W. Phase inversion in abnormal O/W/O emulsions: effect of surfactant concentration. Ind. Eng. Chem. Res., 2002, 41, 6033-6041.
34. Shinoda, K.; Friberg, S.E. Factors affecting the phase inversion temperature in an emulsion. In: Emulsions and solubilization; Shinoda, K.; Friberg, S.E., Eds.; Wiley-Interscience: New York, 1986, pp. 96-123.
35. Friberg, S.E.; Goldsmith, L.B.; Hilton, M.L. Theory of emulsions. In: Pharmaceutical dosage forms: disperse systems; Lieberman, H.A.; Rieger M.M.; Banker, G.S., Eds.; Marcel Dekker Inc.: New York, 1988, pp. 49-91.
36. Vaessen, G.E.J.; Stein, H.N. The applicability of catastrophe theory to emulsion phase inversion. J. Colloid Interface Sci., 1995, 176(2), 378-387.
37. Zerfa, M.; Sajjadi, s.; Brooks, B.W. Phase behaviour of polymer emulsions during the phase inversion process in the presence of non-ionic surfactants. Colloids Surf. A, 2001, 178, 41-48.
38. Salager, J.L.; Forgiarini, A.; Marquéz, L.; Peña, A.; Pizzino, A.; Rodriguez, M.P.; González, M.R. Using emulsion inversion in industrial process. Adv. Colloid Interface Sci., 2004, 259, 108-109.
39. Li, X.; Anton, N.; Vandamme, T. Nano-emulsions: Overview and Applications. In Nanopharmaceutics: the potential application of nanomaterials; Liang, X., Ed.; World Scientific: Singapore, 2013; pp. 21-48.
40. Kunieda, H.; Fukui, Y.; Uchiyama, H.; Solans, C. Spontaneous formation of highly concentrated water-in-oil emulsions (gelemulsions). Langmuir, 1996, 12(9), 2136-2140.
41. Ostertag, F.; Weiss, J.; McClements, D. J. Low-energy formation of edible nanoemulsions: factors influencing droplet size produced by emulsion phase inversion. J. Colloid Interface Sci., 2012, 388(1), 95-102.
42. Thiagarajan, P.; Ravi Theaj Prakash U. Nanoemulsions for drug delivery through different routes. Res Biotechnol, 2011, 2(3), 1-13.
43. Thakur, N.; Garg, G.; Sharma, P. K.; Kumar, N. Nanoemulsions: a review on various pharmaceutical applications. Global J. Pharmacol., 2012, 6(3), 222-225.
44. Shah, P.; Bhalodia, D.; Shelat, P. Nanoemulsion: a pharmaceutical review. Sys. Rev. Pharm., 2010, 11, 24-32.
45. Lu, Y.; Qi, J.; Wu, W. Absorption, disposition and pharmacokinetics of nanoemulsions. Curr. Drug Metab., 2012, 13(4):396-417.
46. Gao, F.; Zhang, Z.; Bu, H.; Huang, Y.; Gao, Z.; Shen, J.; Zhao, C.; Li, Y. Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: Performance and mechanism. J. Control. Release, 2011, 149(2), 168-174.
47. Shakeel, F.; Baboota, S.; Ahuja, A.; Ali, J.; Shafiq, S. Skin permeation mechanism and bioavailability enhancement of celecoxib from transdermally applied nanoemulsion. J. Nanobiotechnol., 2008, 6, 8.
48. Patel, R. P.; Joshi, J. R. An overview on nanoemulsion: A novel approach. Int. J. Pharm. Sci. Res., 2012, 3(12), 4640-4650.
49. Saberi, A. H.; Fang, Y.; McClements, D. J. Fabrication of vitamin E-enriched nanoemulsions by spontaneous emulsification: Effect of propylene glycol and ethanol on formation, stability, and properties. Food Res. Int., 2013, 54(1), 812-820.
50. Fortuna, A.; Alves, G.; Serralheiro, A.; Sousa, J.; Falcão, A. Intranasal delivery of systemic-acting drugs: small-molecules and biomacromolecules. Eur. J. Pharm. Biopharm., 2014, doi:10.1016/j.ejpb.2014.03.004.
51. Rossi, S. Australian Medicines Handbook, Australian Medicines Handbook Pty Ltd: Adelaide, 2014.
52. Djupesland, P. G. Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review. Drug Deliv. Transl. Res., 2013, 3(1), 42-62.
53. Kästner, W. Pharmacological Properties. In Surfactant Science Series. Anionic Surfactants: Biochemistry, Toxicology, Dermatology; Gloxhuber, C., Klunstler, K., Eds.; Marcel Dekker Inc.: New York, USA, 1992; Vol. 43, pp 419-447.
54. Illum, L. Nasal drug delivery - recent developments and future prospects. J. Control. Release, 2012, 161(2), 254-263.
55. Illum, L. Nasal drug delivery: new developments and strategies. Drug Discov. Today, 2002, 7(23), 1184-1189.
56. Ali, J.; Ali, M.; Baboota, S.; Kaur Sahni, J.; Ramassamy, C.; Dao, L. Potential of nanoparticulate drug delivery systems by intranasal administration. Curr. Pharm. Des., 2010, 16(14), 1644-1653.
57. Yu, C.; Gu, P.; Zhang, W.; Qi, N.; Cai, C.; He, H.; Tang, X. Preparation and evaluation of zolmitriptan submicron emulsion for rapid and effective nasal absorption in beagle dogs. Drug Dev. Ind. Pharm., 2011, 37(12), 1509-1516.
58. Jain, R.; Patravale, V. B. Development and evaluation of nitrendipine nanoemulsion for intranasal delivery. J. Biomed. Nanotechnol., 2009, 5(1), 62-68.
59. Mahajan, H. S.; Dinger, S. B. Design and in vitro evaluation of nanoemulsion for nasal delivery of artemether. Indian J. Novel Drug Deliv., 2011, 3(4), 272-277.
60. Hosny, K. M.; Banjar, Z. M. The formulation of a nasal nanoemulsion zaleplon in situ gel for the treatment of insomnia. Expert Opin. Drug Deliv., 2013, 10(8), 1033-1041.
61. MacLennan, S. J.; Cambridge, D.; Whiting, M. V.; Marston, C.; Martin, G. R. Cranial vascular effects of zolmitriptan, a centrally active 5-HT1B/1D receptor partial agonist for the acute treatment of migraine. Eur. J. Pharmacol., 1998, 361(2), 191-197.
62. Colussi, D.; Parisot, C.; Legay, F.; Lefèvre, G. Binding of artemether and lumefantrine to plasma proteins and erythrocytes. Eur. J. Pharm. Sci., 1999, 9(1), 9-16.
63. Gugulothu, D.; Pathak, S.; Suryavanshi, S.; Sharma, S.; Patravale, V. Self-microemulsifiyng suppository formulation of β-artemether. AAPS PharmSciTech, 2010, 11(3), 1179-1184.
64. Waghmare, A.; Pore, Y.; Kuchekar, B. Development and characterization of zaleplon solid dispersion systems: a technical note. AAPS PharmSciTech, 2008, 9(2), 536-543.
65. Drover, D.; Lemmens, H.; Naidu, S.; Cevallos, W.; Darwish, M.; Stanski, D. Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem. Clin. Ther., 2000, 22(12), 1443-1461.
66. Ekelund, K.; Östh, K.; Påhlstorp, C.; Björk, E.; Ulvenlund, S.; Johansson, F. Correlation between epithelial toxicity and surfactant structure as derived from the effects of polyethyleneoxide surfactants on caco--‐2 cell monolayers and pig nasal mucosa. J. Pharm. Sci., 2005, 94(4), 730-744.
67. Csaba, N.; Garcia-Fuentes, M.; Alonso, M. J. Nanoparticles for nasal vaccination. Adv. Drug Deliv. Rev., 2009, 61(2), 140-157.
68. Makidon, P. E.; Nigavekar, S. S.; Bielinska, A. U.; Mank, N.; Shetty, A. M.; Suman, J.; Knowlton, J.; Myc, A.; Rook, T.; Baker Jr, J. R. Characterization of stability and nasal delivery systems for immunization with nanoemulsion-based vaccines. J. Aerosol. Med. Pulm. Drug. Deliv., 2010, 23(2), 77-89.
69. Stanberry, L.; Simon, J.; Johnson, C.; Robinson, P.; Morry, J.; Flack, M.; Gracon, S.; Myc, A.; Hamouda, T.; Baker Jr, J. Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W805EC combined with approved seasonal influenza antigens. Vaccine, 2012, 30(2), 307-316.
70. Bielinska, A. U.; Makidon, P. E.; Janczak, K. W.; Blanco, L. P.; Swanson, B.; Smith, D. M.; Pham, T.; Szabo, Z.; Kukowska-Latallo, J. F.; Baker, J. R., Jr Distinct pathways of humoral and cellular immunity induced with the mucosal administration of a nanoemulsion adjuvant. J. Immunol., 2014, 192(6), 2722-2733.
71. Davis, S. Nasal vaccines. Adv. Drug Deliv. Rev., 2001, 51(1), 21-42.
72. Makidon, P. E.; Belyakov, I. M.; Blanco, L. P.; Janczak, K. W.; Landers, J.; Bielinska, A. U.; Groom, J. V.; Baker, J. R. Nanoemulsion mucosal adjuvant uniquely activates cytokine production by nasal ciliated epithelium and induces dendritic cell trafficking. Eur. J. Immunol., 2012, 42(8), 2073-2086.
73. Wong, P. T.; Wang, S. H.; Ciotti, S.; Makidon, P. E.; Smith, D. M.; Fan, Y.; Schuler, C. F.; Baker, J. R. Formulation and Characterization of Nanoemulsion Intranasal Adjuvants: Effects of Surfactant Composition on Mucoadhesion and Immunogenicity. Mol. Pharmaceutics, 2014, 11, 531-544.
74. Neutra, M. R.; Kozlowski, P. A. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol., 2006, 6(2), 148-158.
75. Chadwick, S.; Kriegel, C.; Amiji, M. Nanotechnology solutions for mucosal immunization. Adv. Drug Deliv. Rev., 2010, 62(4), 394-407.
76. Das, S. C.; Hatta, M.; Wilker, P. R.; Myc, A.; Hamouda, T.; Neumann, G.; Baker Jr., J. R.; Kawaoka, Y. Nanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine. Vaccine, 2012, 30(48), 6871-6877.
77. Myc, A.; Kukowska-Latallo, J. F.; Smith, D. M.; Passmore, C.; Pham, T.; Wong, P.; Bielinska, A. U.; Baker Jr., J. R. Nanoemulsion nasal adjuvant W805EC induces dendritic cell engulfment of antigen-primed epithelial cells. Vaccine, 2013, 31(7), 1072-1079.
78. Lindell, D. M.; Morris, S. B.; White, M. P.; Kallal, L. E.; Lundy, P. K.; Hamouda, T.; Baker Jr, J. R.; Lukacs, N. W. A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease. PLoS One, 2011, 6(7), e21823.
79. Ledet, G.; Bostanian, L. A.; Mandel, T. K. Nanoemulsions as a Vaccine Adjuvant. In Bioengineered Nanomaterials; Tiwari, A., Tiwari, A., Eds.; CRC Press: Boca Raton, 2013; pp 125-148.
80. Hamouda, T.; Sutcliffe, J. A.; Ciotti, S.; Baker, J. R., Jr Intranasal immunization of ferrets with commercial trivalent influenza vaccines formulated in a nanoemulsion-based adjuvant. Clin. Vaccine Immunol., 2011, 18(7), 1167-1175.
81. Lycke, N. Recent progress in mucosal vaccine development: potential and limitations. Nat. Rev. Immunol., 2012, 12(8), 592-605.
82. NanoBio Corporation. NanoStaT Platform. http://www.nanobio.com/Platform-Technology/NanoStat-Platform.html (Accessed August 10, 2014).
83. Bielinska, A. U.; Janczak, K. W.; Landers, J. J.; Markovitz, D. M.; Montefiori, D. C.; Baker Jr, J. R. Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses, 2008, 24(2), 271-281.
84. Makidon, P.; Knowlton, J.; Groom II, J.; Blanco, L.; LiPuma, J.; Bielinska, A.; Baker Jr, J. Induction of immune response to the 17 kDa OMPA Burkholderia cenocepacia polypeptide and protection against pulmonary infection in mice after nasal vaccination with an OMP nanoemulsion-based vaccine. Med. Microbiol. Immunol., 2010, 199(2), 81-92.
85. Dhuria, S. V.; Hanson, L. R.; Frey, W. H. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J. Pharm. Sci., 2010, 99(4), 1654-1673.
86. Wu, H.; Hu, K.; Jiang, X. From nose to brain: understanding transport capacity and transport rate of drugs. Expert Opin. Drug Deliv., 2008, 5(10), 1159-1168.
87. Illum, L. Transport of drugs from the nasal cavity to the central nervous system. Eur. J. Pharm. Sci., 2000, 11(1), 1-18.
88. Wen, M. M. Olfactory targeting through intranasal delivery of biopharmaceutical drugs to the brain-current development. Discov. Med., 2011, 11(61), 497-503.
89. Kumar, M.; Pathak, K.; Misra, A. Formulation and characterization of nanoemulsion-based drug delivery system of risperidone. Drug Dev. Ind. Pharm., 2009, 35(4), 387-395.
90. Kumar, M.; Misra, A.; Babbar, A.; Mishra, A.; Mishra, P.; Pathak, K. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int. J. Pharm., 2008, 358(1), 285-291.
91. Kumar, M.; Misra, A.; Mishra, A.; Mishra, P.; Pathak, K. Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting. J. Drug Target., 2008, 16(10), 806-814.
92. Bahadur, S.; Pathak, K. Buffered Nanoemulsion for Nose to Brain Delivery of Ziprasidone Hydrochloride: Preformulation and Pharmacodynamic Evaluation. Curr. Drug Deliv., 2012, 9(6), 596-607.
93. Sood, S.; Jain, K.; Gowthamarajan, K. Optimization of curcumin nanoemulsion for intranasal delivery using design of experiment and its toxicity assessment. Colloid Surface B, 2014, 113, 330-337.
94. Mahajan, H. S.; Mahajan, M. S.; Nerkar, P. P.; Agrawal, A. Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting. Drug Deliv., 2014, 21(2), 148-154.
95. Bhanushali, R.; Gatne, M.; Gaikwad, R.; Bajaj, A.; Morde, M. Nanoemulsion based intranasal delivery of antimigraine drugs for nose to brain targeting. Indian J. Pharm. Sci., 2009, 71(6), 707-709.
96. Samia, O.; Hanan, R.; Kamal, E. T. Carbamazepine Mucoadhesive Nanoemulgel (MNEG) as brain targeting delivery system via the olfactory mucosa. Drug Deliv., 2012, 19(1), 58-67.
97. Mustafa, G.; Ahmad, N.; Baboota, S.; Ali, J.; Ahuja, A. UHPLC/ESI--‐Q--‐TOF--‐MS method for the measurement of dopamine in rodent striatal tissue: A comparative effects of intranasal administration of ropinirole solution over nanoemulsion. Drug Test. Anal., 2013, 5(8), 702-709.
98. Vyas, T. K.; Babbar, A.; Sharma, R.; Singh, S.; Misra, A. Preliminary brain-targeting studies on intranasal mucoadhesive microemulsions of sumatriptan. AAPS PharmSciTech, 2006, 7(1), E49-E57.
99. Vyas, T. K.; Babbar, A.; Sharma, R.; Singh, S.; Misra, A. Intranasal mucoadhesive microemulsions of clonazepam: preliminary studies on brain targeting. J. Pharm. Sci., 2006, 95(3), 570-580.
100. Jogani, V. V.; Shah, P. J.; Mishra, P.; Mishra, A. K.; Misra, A. R. Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting. Alzheimer Dis. Assoc. Disord., 2008, 22(2), 116-124.
101. Vyas, T. K.; Babbar, A.; Sharma, R.; Misra, A. Intranasal mucoadhesive microemulsions of zolmitriptan: preliminary studies on brain-targeting. J. Drug Target., 2005, 13(5), 317-324.
102. Jain, N.; Akhter, S.; Jain, G.K.; Khan, Z.I.; Khar, R.K.; Ahmad, F.J. Antiepileptic intranasal amiloride loaded mocoadhesive nanoemulsion: development and safety assessment. J. Biomed. Nanotechnol., 2011, 7, 142-143.
103. Davis, K.L.; Powchick, P. Tacrine. Lancet, 1995, 345(8950), 625-630.